Assembly biosciences announces presentation during the 2022 h.c. wainwright bioconnect virtual conference

South san francisco, calif., jan. 06, 2022 (globe newswire) -- assembly biosciences, inc. (nasdaq: asmb), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis b virus (hbv) and other viral diseases, today announced that john mchutchison, ao, md, chief executive officer and president, will present during the hc wainwright virtual bioconnect conference, january 10-13, 2022.
ASMB Ratings Summary
ASMB Quant Ranking